A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

NCT06891833 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: BL-M07D1
DRUG: Pertuzumab

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]